This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Boryung Co.,Ltd.


Boryung is a pharmaceutical company based in South Korea and currently has a total of 27 affiliates with a diverse business portfolio ranging from research and development of new drugs to manufacturing and sales of drug products, APIs, and consumer products. Since its foundation in 1957, Boryung has been innovating and taking on challenges to become an indispensable contributor to human health. Boryung's steady growth is evidenced by increases in both sales and operating profit(s) in 2022 - sales increased by 21% (total sales of 760.5 billion KRW) and operating profit(s) increased by 37% (total operating profit(s) of 56.6 billion KRW). As a result of continuous developments, Boryung has become the major leading company in the domestic pharmaceutical market for hypertension, diabetes, and cancer sectors.In order to leap forward as the No. 1 pharmaceutical company in South Korea and into a global innovative pharmaceutical company, Boryung continuously strives to focus on strengthening research capabilities and developing innovative medicines with our innovative drug research center.Based on the diverse R&D experiences accumulated over the past 60 years, Boryung is expanding our research and drug development capacity to NCE(New Chemical Entity) and thus, aggressively investing in anticancer drugs as a future growth catalyst.Specifically, BR101801 is a first-in-class anticancer drug that triple-inhibits PI3K delta/gamma and DNA-PK and is currently being developed by Boyrung as a treatment for peripheral T-cell lymphomas (PTCL).